Evidence map›Paper›PMID 34384824›Full record

ArticleAntiviral research2021

Simple and rapid high-throughput assay to identify HSV-1 ICP0 transactivation inhibitors.

Cindy Y Ly, Chunmiao Yu, Peter R McDonald, Anuradha Roy, David K Johnson, David J Davido

Abstract read
In one paragraph

Article in Antiviral research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. HSV-1 ICP0 Dimer Domain Adopts a Novel β-barrel Fold.bioRxiv : the preprint server for biology · 2024
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cindy Y LyDepartment of Molecular Biosciences, The University of Kansas, Lawrence, KS, 66045, USA.
Chunmiao YuDepartment of Molecular Biosciences, The University of Kansas, Lawrence, KS, 66045, USA.
Peter R McDonaldHigh Throughput Screening Laboratory, The University of Kansas, Lawrence, KS, 66047, USA.
Anuradha RoyHigh Throughput Screening Laboratory, The University of Kansas, Lawrence, KS, 66047, USA.
David K JohnsonComputational Chemical Biology Core, The University of Kansas, Lawrence, KS, 66047, USA.
David J DavidoDepartment of Molecular Biosciences, The University of Kansas, Lawrence, KS, 66045, USA. Electronic address: ddavido@ku.edu.

Funding

Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
TRAINING GRANT IN DYNAMIC ASPECTS OF CHEMICAL BIOLOGYT32GM008545 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LAMB, AUDREY L · 1994 to 2019
$4.9M
NIGMS NIH HHS P20 GM113117NIGMS NIH HHS T32 GM008545
6 · The paper itself

Abstract

Herpes simplex virus 1 (HSV-1) is a ubiquitous virus that results in lifelong infections due to its ability to cycle between lytic replication and latency. As an obligate intracellular pathogen, HSV-1 exploits host cellular factors to replicate and aid in its life cycle. HSV-1 expresses infected cell protein 0 (ICP0), an immediate-early regulator, to stimulate the transcription of all classes of viral genes via its E3 ubiquitin ligase activity. Here we report an automated, inexpensive, and rapid high-throughput approach to examine the effects of small molecule compounds on ICP0 transactivator function in cells. Two HSV-1 reporter viruses, KOS6β (wt) and dlx3.1-6β (ICP0-null mutant), were used to monitor ICP0 transactivation activity through the HSV-1 ICP6 promoter:lacz expression cassette. A ≥10-fold difference in β-galactosidase activity was observed in cells infected with KOS6β compared to dlx3.1-6β, demonstrating that ICP0 potently transactivates the ICP6 promoter. We established the robustness and reproducibility with a Z'-factor score of ≥0.69, an important criterium for high-throughput analyses. Approximately 19,000 structurally diverse compounds were screened and 76 potential inhibitors of the HSV-1 transactivator ICP0 were identified. We expect this assay will aid in the discovery of novel inhibitors and tools against HSV-1 ICP0. Using well-annotated compounds could identify potential novel factors and pathways that interact with ICP0 to promote HSV-1 gene expression.

Indexed as

Data CollectionGene ExpressionHerpesvirus 1, HumanHigh-Throughput Screening AssaysImmediate-Early ProteinsPromoter Regions, GeneticReproducibility of ResultsSmall Molecule LibrariesTranscriptional ActivationUbiquitin-Protein LigasesImmediate-Early ProteinsSmall Molecule LibrariesUbiquitin-Protein LigasesVmw110 protein, Human herpesvirus 1Herpes simplex virus 1High-throughput assayInfected cell protein 0

Identifiers

PMID34384824
PMCPMC8686521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.